Shanghai Shen Lian Biomedical Corporation (SHA:688098)

SHA:688098 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	291.32	301.93	300.14	327.87	357.79	337.39
Other Revenue	1.48	1.48	1.34	0.72	0.64	0.34
Revenue	292.81	303.41	301.49	328.59	358.43	337.73
Revenue Growth (YoY)	-5.66%	0.64%	-8.25%	-8.32%	6.13%	33.06%
Cost of Revenue	120.35	120.62	87.89	81.38	87.01	55.1
Gross Profit	172.46	182.8	213.59	247.21	271.42	282.63
Selling, General & Admin	138.04	155.91	134.72	128.69	120.97	123.35
Research & Development	42.82	49.36	44.53	39.04	34.95	31.91
Other Operating Expenses	1.97	2.76	3.54	3.43	3.57	2.97
Operating Expenses	188.66	216.47	185.9	179.66	161.13	157.75
Operating Income	-16.2	-33.67	27.7	67.56	110.29	124.88
Interest Expense	-0.22	-0.02	-	-	-	-
Interest & Investment Income	0.82	2.6	4.42	3.99	11.91	16.8
Currency Exchange Gain (Loss)	0	0	-0.02	-0.05	0.01	0.04
Other Non Operating Income (Expenses)	0.15	-0.08	-0.08	-0.01	0.07	-0
EBT Excluding Unusual Items	-15.45	-31.17	32.02	71.49	122.29	141.72
Gain (Loss) on Sale of Investments	1.45	0.88	2.35	0.35	1.78	0.75
Gain (Loss) on Sale of Assets	0.02	-0.25	-0.4	0.14	-0.6	-0.05
Asset Writedown	-28.14	-28.17	-	-0.24	-	-
Other Unusual Items	3.18	1.91	2.3	2.82	2.52	7.57
Pretax Income	-38.94	-56.79	36.27	74.55	125.98	149.99
Income Tax Expense	-4.19	-8.05	6.41	13.58	21.52	20.63
Earnings From Continuing Operations	-34.75	-48.75	29.85	60.97	104.46	129.37
Minority Interest in Earnings	4.41	4.01	1.67	0.13	5.74	0.15
Net Income	-30.34	-44.74	31.52	61.1	110.2	129.51
Net Income to Common	-30.34	-44.74	31.52	61.1	110.2	129.51
Net Income Growth	-	-	-48.42%	-44.55%	-14.91%	66.14%
Shares Outstanding (Basic)	411	407	394	407	408	405
Shares Outstanding (Diluted)	411	407	394	407	408	418
Shares Change (YoY)	-6.19%	3.23%	-3.28%	-0.20%	-2.31%	12.54%
EPS (Basic)	-0.07	-0.11	0.08	0.15	0.27	0.32
EPS (Diluted)	-0.07	-0.11	0.08	0.15	0.27	0.31
EPS Growth	-	-	-46.67%	-44.44%	-12.90%	47.62%
Free Cash Flow	-15.28	4.45	-126.11	-84.04	-98.04	-51.83
Free Cash Flow Per Share	-0.04	0.01	-0.32	-0.21	-0.24	-0.12
Dividend Per Share	-	-	0.035	0.080	-	0.100
Dividend Growth	-	-	-56.25%	-	-	25.00%
Gross Margin	58.90%	60.25%	70.85%	75.23%	75.72%	83.69%
Operating Margin	-5.53%	-11.10%	9.19%	20.56%	30.77%	36.98%
Profit Margin	-10.36%	-14.75%	10.45%	18.59%	30.75%	38.35%
Free Cash Flow Margin	-5.22%	1.47%	-41.83%	-25.57%	-27.35%	-15.35%
EBITDA	55.13	34.15	90.85	124.49	153.91	145.63
EBITDA Margin	18.83%	11.25%	30.13%	37.89%	42.94%	43.12%
D&A For EBITDA	71.33	67.82	63.15	56.94	43.62	20.75
EBIT	-16.2	-33.67	27.7	67.56	110.29	124.88
EBIT Margin	-5.53%	-11.10%	9.19%	20.56%	30.77%	36.98%
Effective Tax Rate	-	-	17.69%	18.21%	17.08%	13.75%
Revenue as Reported	292.81	303.41	301.49	-	358.43	337.73

Source: S&P Global Market Intelligence. Standard template. Financial Sources.